Role of sentinel lymph node biopsy in patients with thin melanoma

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 7, Issue 3, 2009, Pages 308-317

  Andtbacka, Robert H I ^a   Gershenwald, Jeffrey E ^b  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Melanoma; Metastasis; Sentinel lymph node; Thin

Indexed keywords

AGE; ARTICLE; CANCER GROWTH; CANCER INCIDENCE; CANCER SIZE; CANCER STAGING; CLINICAL DECISION MAKING; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; GROWTH CURVE; HUMAN; INFORMATION RETRIEVAL; LYMPH NODE METASTASIS; LYMPHOCYTIC INFILTRATION; MEDLINE; MELANOMA; MITOSIS RATE; OCCULT CANCER; PREDICTION; PROGNOSIS; RELIABILITY; RISK ASSESSMENT; SENTINEL LYMPH NODE BIOPSY; SEX DIFFERENCE; TREATMENT INDICATION; TUMOR REGRESSION; ULCER;

EID: 63449113394     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2009.0023     Document Type: Article

References (64)

1. Ries LA, Melbert D, Krapcho M, et al., eds. SEER Cancer Statistics Review, 1975-2005. Available at: http://seer.cancer.gov/csr/1975_2005/ index.html. Accessed February 6, 2009.
2. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin 2008;58:71-96.
3. Batch CM, Buzaid AC, Soong SJ, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 2001;19:3635-3648.
4. Balch CM, Soong SJ, Gershenwald JE, et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncot 2001;19:3622-3634.
5. Thompson JF, Shaw HM. Is sentinel lymph node biopsy appropriate in patients with thin melanomas: too early to tell? Ann Surg Oncol 2006;13:279-281.
6. Balch CM, Buzaid AC, Atkins MB, et al. A new American joint Committee on Cancer staging system for cutaneous melanoma. Cancer 2000;88:1484-1491.
7. Gershenwald JE, Thompson W, Mansfield PF, et al. Multiinstitutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients. J Clin Oncol 1999;17:976-983.
8. Gershenwald JE, Batch CM, Thompson JF. Intraoperative mapping and sentinel node technology in patients with melanoma. In: Batch CM, ed. Cutaneous Melanoma, 5th ed. St. Louis: Quality Medical Publishing Inc.; in press.
9. Morton DL, Wen DR, Wong JH, et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg 1992;127:392-399.
10. Thompson JF, McCarthy WH, Bosch CM, et al. Sentinel lymph node status as an indicator of the presence of metastatic melanoma in regional lymph nodes. Melanoma Res 1995;5:255-260.
11. Agnese DM, Abdessalam SF, Burak WE Jr, et al. Costoeffectiveness of sentinel lymph node biopsy in thin melanomas. Surgery 2003;134:542-547; discussion 547-548.
12. Bedrosian I, Faries MB, Guerry DT, et al. Incidence of sentinel node metastasis in patients with thin primary melanoma (< or = I mm) with vertical growth phase. Ann Surg Oncol 2000;7:262-267.
13. Bleicher RJ, Essner R, Foshag LJ, et al. Role of sentinel lymphadenectomy in thin invasive cutaneous melanomas. J Clin Oncol 2003;21:1326-1331.
14. Cecchi R, Buralli L, Innocenti S, et al. Sentinel lymph node biopsy in patients with thin melanomas. J Dermatol 2007;34:512-515.
15. Cecchi R, Pavesi M, Buralli L, et al. Tumour regression does not increase the risk of sentinel node involvement in thin melanomas. Chir Ital 2008;60:257-260.
16. Hershko DD, Robb BW, Lowy AM, et al. Sentinel lymph node biopsy in thin melanoma patients. J Surg Oncol 2006;93:279-285.
17. Jacobs IA, Chang CK, DasGupta TK, et al. Role of sentinel lymph node biopsy in patients with thin (<1 mm) primary melanoma. Ann Surg Oncol 2003;10:558-561.
18. Kesmodel SB, Karakousis GC, Bothyl JD, et al. Mitotic rate as a predictor of sentinel lymph node positivity in patients with thin melanomas. Ann Surg Oncol 2005;12:449-458.
19. Koskivuo I, Suominen E, Niinikoski J, et al. Sentinel node metastasectomy in thin
20. Kruper LL, Spitz FR, Czemiecki BJ, et al. Predicting sentinel node status in AJCC stage, I/II primary cutaneous melanoma. Cancer 2006;107:2436-2445.
21. Lowe JB, Hurst E, Moley JF, et al. Sentinel lymph node biopsy in patients with thin melanoma. Arch Dermatol 2603;139:617-621.
22. Morris KT, Busam KJ, Bero S, et al. Primary cutaneous melanoma with regression does not require a lower threshold for sentinel lymph node biopsy. Ann Surg Oncol 2008;15:316-322.
23. Nahabedian MY, Tufaro AP, Manson PN. Sentinel lymph node biopsy for the T1 (thin) melanoma: is it necessary? Ann Plast Surg 2003;50:601-606.
24. Olah J, Gyulai R, Korom J, et al. Tumour regression predicts higher risk of sentinel node involvement in thin cutaneous melanomas. Br J Dermatol 2003;149:662-663.
25. Oliveira Filho RS, Ferreira LM, Biasi LJ, et al. Vertical growth phase and positive sentinel node in thin melanoma. Braz J Med Biol Res 2003;36:347-350.
26. Puleo CA, Messina JL, Riker AI, et al. Sentinel node biopsy for thin melanomas: which patients should be considered? Cancer Control 2005;12:230-235.
27. Ranieri JM, Wagner JD, Wenck S, et al. The prognostic importance of sentinel lymph node biopsy in thin melanoma. Ann Surg Oncol 2006;13:927-932.
28. Sondak VK, Taylor JM, Sabel MS, et al. Mitotic rate and younger age are predictors of sentinel lymph node positivity: lessons learned from the generation of a probabilistic model. Ann Surg Oncol 2004;11:247-258.
29. Stitzenberg KB, Groben PA, Stern SL, et al. Indications for lymphatic mapping and sentinel lymphadenectomy in patients with thin melanoma (Breslow thickness < or =1.0 mm). Ann Surg Oncol 2004;11:900-906.
30. Taylor RC, Patel A, Panageas KS, et al. Tumor-infiltrating lymphocytes predict sentinel lymph node positivity in patients with cutaneous melanoma. J Clin Oncol 2007;25:869-875.
31. Vaquerano J, Kraybill WG, Driscoll DL, et al. American Joint Committee on Cancer clinical stage as a selection criterion for sentinel lymph node biopsy in thin melanoma. Ann Surg Oncol 2006;13:198-204.
32. Wong SL, Brady MS, Busam KJ, et al. Results of sentinel lymph node biopsy in patients with thin melanoma. Ann Surg Oncol 2006;13:302-309.
33. Wright BE, Scheri RP, Ye X, et al. Importance of sentinel lymph node biopsy in patients with thin melanoma. Arch Surg 2008;143:892-899; discussion 899-900.
34. Edge S, Byrd D, Carducci M, eds. Melanoma of the skin. In: AJCC Cancer Staging Manual, 7th ed. New York: Springer; in press
35. Coit DG, Andtbacka R, Bichakjian, CK, et al. NCCN Clinical practice Guidelines in Oncology: Melanoma. Version 2, 2009. Available at: http://www.nccn.org/professionals/physician_gls/f_guidelines.asp. Accessed February 6, 2009.
36. Balch CM, Morton DL, Gershenwald JE, et al. Sentinel node biopsy and standard of care for melanoma. J Am Acad Dermatol, in press
37. AJCC Cancer Staging Manual, 5th ed. Philadelphia: Lippincott-Raven Publishers; 1997.
38. Clark WH Jr, Elder DE, Guerry DT, et al. Model predicting survival in stage I melanoma based on tumor progression. J Natl Cancer Inst 1989;81:1893-1904.
39. Gimotty PA, Guerry D, Ming ME, et al. Thin primary cutaneous malignant melanoma: a prognostic tree for 10-year metastasis is more accurate than American Joint Committee on Cancer staging. J Clin Oncol 2004;22:3668-3676.
40. Szymik B, Woosley JT. Further validation of the prognostic model for stage I malignant melanoma based on tumor progression. J Cutan Pathol 1993;20:50-53.
41. Blessing K, McLaren KM. Histological regression in primary cutaneous melanoma: recognition, prevalence and significance. Histopathology 1992;20:315-322.
42. Slingluff CL Jr, Vollmer RT, Reintgen DS, et al. Lethal "thin" malignant melanoma. Identifying patients at risk. Ann Surg 1988;208:150-161.
43. Tefany FJ, Barnetson RS, Halliday GM, et al. Immunocytochemical analysis of the cellular infiltrate in primary regressing and non-regressing malignant melanoma. J Invest Dermatol 1991;97:197-202.
44. Guitart J, Lowe L, Piepkorn M, et al. Histological characteristics of metastasizing thin melanomas: a case-control study of 43 cases. Arch Dermatol 2002;138:603-608.
45. Brogelli L, Reali UM, Moretti S, et al. The prognostic significance of histologic regression in cutaneous melanoma. Melanoma Res 1992;2:87-91.
46. Kelly JW, Sagebiel RW, Blois MS. Regression in malignant melanoma. A histologic feature without independent prognostic significance. Cancer 1985;56:2287-2291.
47. Czarnetzki BM, Denter M, Brocker EB, et al. Clinical features of superficial spreading melanomas with zones of regression. J Cancer Res Clin Oncol 1984;107:225-228.
48. Clemente CG, Mihm MC Jr, Bufalino R, et al. Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer 1996;77:1303-1310
49. Chao C, Martin RC II, Ross MI, et al. Correlation between prognostic factors and increasing age in melanoma. Ann Surg Oncol 2004;11:259-264.
50. Rousseau DL Jr, Ross MI, Johnson MM, et al. Revised American Joint Committee on Cancer staging criteria accurately predict sentinel lymph node positivity in clinically node-negative melanoma patients. Ann Surg Oncol 2003;10:569-574.
51. Thompson JF, Shaw HM. Should tumor mitotic rate and patient age, as well as tumor thickness, be used to select melanoma patients for sentinel node biopsy? Ann Surg Oncol 2004;11:233-235.
52. Gershenwald JE, Thompson JF, Warneke C. Defining indications for SLN biopsy in patients with thin melanoma - preliminary results of an international thin melanoma working group. Presented at the 6th Biennial International Sentinel Node Society Meeting; Sydney, Australia; February 18-20, 2008.
53. Karakousis GC, Gimotty PA, Botbyl JD, et al. Predictors of regional nodal disease in patients with thin melanomas. Ann Surg Oncol 2006;13:533-541.
54. Thompson JF, Shaw HM. Sentinel node metastasis from thin melanomas with vertical growth phase. Ann Surg Oncol 2000;7:251-252.
55. Gershenwald JE, Andtbacka RH, Prieto VG, et al. Microscopic tumor burden in sentinel lymph nodes predicts synchronous nonsentinel lymph node involvement in patients with melanoma. J Clin Oncol 2008;26:4296-4303.
56. Lee JH, Essner R, Torisu-Itakura H, et al. Factors predictive of tumor-positive nonsentinel lymph nodes after tumor-positive sentinel lymph node dissection for melanoma. J Clin Oncol 2004;22:3677-3684.
57. McMasters KM, Wong SL, Edwards MJ, et al. Frequency of nonsentinel lymph node metastasis in melanoma. Ann Surg Oncol 2002;9:137-141.
58. Sabel MS, Griffith K, Sondak VK, et al. Predictors of nonsentinel lymph node positivity in patients with a positive sentinel node for melanoma. J Am Coll Surg 2005;201:37-47.
59. van Akkooi AC, de Wilt JH, Verhoef C, et al. Clinical relevance of melanoma micrometastases (<0.1 mm) in sentinel nodes: are these nodes to be considered negative? Ann Oncol 2006;17:1578-1585.
60. McKinnon JG, Yu XQ, McCarthy WH, et al. Prognosis for patients with thin cutaneous melanoma: long-term survival data from New South Wales Central Cancer Registry and the Sydney Melanoma Unit. Cancer 2003;98:1223-1231.
61. Karakousis GC, Gimotty PA, Czerniecki BJ, et al. Regional nodal metastatic disease is the strongest predictor of survival in patients with thin vertical growth phase melanomas: a case for SLN Staging biopsy in these patients. Ann Surg Oncol 2007;14:1596-1603.
62. McMasters KM. What good is sentinel lymph node biopsy for melanoma if it does not improve survival? Ann Surg Oncol 2004;11:810-812.
63. McMasters KM, Reintgen DS, Ross MI, et al. Sentinel lymph node biopsy for melanoma: controversy despite widespread agreement. J Clin Oncol 2001;19:2851-2855.
64. Morton DL, Cochran AJ, Thompson JF, et al. Sentinel node biopsy for early-stage melanoma: accuracy and morbidity in MSLT-I, an international multicenter trial. Ann Surg 2005;242:302-311; discussion 311-313.